logo
Plus   Neg
Share
Email

IGI Laboratories Names Jason Grenfell-Gardner CEO

IGI Laboratories, Inc. (IG) Monday said Jason Grenfell-Gardner has been appointed President and Chief Executive Officer of the firm, effective July 30.

Jason Grenfell-Gardner brings significant experience in the pharmaceutical industry, with a special focus on generics. He was most recently the Senior Vice President of Sales and Marketing for West-Ward Pharmaceuticals, the US Subsidiary of Hikma Pharmaceuticals.

Jason had a key role in the senior management team there, which grew the business from just over $100 million in 2008 to over $300 million in 2011. He strengthened West-Ward's presence in the sterile injectable space through the acquisition of Baxter International, Inc.'s multisource injectable business in 2011.

Jason originally joined Hikma Pharmaceuticals to lead its initial public offering in 2004, and later headed its business development efforts.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT